TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT04928846: A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squ

Sponsor: AbbVie · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 768 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$787,248

Rescue Site Savings

+$524,832

Unlock Full NCT04928846 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04928846 Rescue Dossier →